$0.15
0.42% today
Nasdaq, Feb 28, 09:04 pm CET
ISIN
US87184Q1076
Symbol
SYRS
Sector
Industry

Syros Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Syros Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
33%
Hold
67%

Syros Pharmaceuticals, Inc. Price Target

Target Price $10.50
Price $0.14
Potential
Number of Estimates 2
2 Analysts have issued a price target Syros Pharmaceuticals, Inc. 2026 . The average Syros Pharmaceuticals, Inc. target price is $10.50. This is higher than the current stock price. The highest price target is
$20.00 13,750.42%
register free of charge
, the lowest is .
A rating was issued by 3 analysts: 1 Analysts recommend Syros Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Syros Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Syros Pharmaceuticals, Inc. stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -5.81 -1.50
22.43% 74.18%
P/E negative

1 Analysts have issued a Syros Pharmaceuticals, Inc. forecast for earnings per share. The average Syros Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.50
Unlock
. This is
50.50% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.50 50.50%
Unlock
, the lowest is
$-1.50 50.50%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-5.81 22.43%
2024
$-1.50 74.18%
Unlock
2025
$-0.95 36.67%
Unlock
2026
$-0.60 36.84%
Unlock
2027
$-0.65 8.33%
Unlock
2028
$-0.65 0.00%
Unlock

P/E ratio

Current -0.05 97.41%
2024
-0.10 100.00%
Unlock
2025
-0.15 50.00%
Unlock
2026
-0.24 60.00%
Unlock
2027
-0.22 8.33%
Unlock
2028
-0.22 0.00%
Unlock

Current Syros Pharmaceuticals, Inc. Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Brookline Capital Locked ➜ Locked Locked Nov 13 2024
HC Wainwright & Co. Locked ➜ Locked Locked Nov 13 2024
JMP Securities Locked ➜ Locked Locked Nov 13 2024
TD Cowen Locked ➜ Locked Locked Nov 13 2024
HC Wainwright & Co. Locked ➜ Locked Locked Nov 01 2024
Analyst Rating Date
Locked
Brookline Capital: Locked ➜ Locked
Nov 13 2024
Locked
HC Wainwright & Co.: Locked ➜ Locked
Nov 13 2024
Locked
JMP Securities: Locked ➜ Locked
Nov 13 2024
Locked
TD Cowen: Locked ➜ Locked
Nov 13 2024
Locked
HC Wainwright & Co.: Locked ➜ Locked
Nov 01 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today